Overexpression of Nemo-like Kinase Promotes the Proliferation and Invasion of Lung Cancer Cells and Indicates Poor Prognosis

Author(s): Lei Lei , Yuan Wang , Yi-Wen Zheng , Liang-Ru Fei , Hao-Yue Shen , Zhi-Han Li , Wen-Jing Huang , Juan-Han Yu , Hong-Tao Xu* .

Journal Name: Current Cancer Drug Targets

Volume 19 , Issue 8 , 2019

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Nemo-like kinase (NLK) is an evolutionarily conserved MAP kinaserelated kinase involved in the pathogenesis of several human cancers.

Objective: The aim of this study was to investigate the expression and role of NLK in lung cancers, and its underlying mechanisms.

Methods: We examined the expression of NLK in lung cancer tissues through western blot analysis. We enhanced or knocked down NLK expression by gene transfection or RNA interference, respectively, in lung cancer cells, and examined expression alterations of key proteins in the Wnt signaling pathway and in epithelial-mesenchymal transition (EMT). We also examined the roles of NLK in the proliferation and invasiveness of lung cancer cells by cell proliferation, colony formation, and Matrigel invasion assays.

Results: NLK expression was found to be significantly higher in lung cancer tissue samples than in corresponding healthy lung tissue samples. Overexpression of NLK correlated with poor prognosis of patients with lung cancer. Overexpression of NLK upregulated β-catenin, TCF4, and Wnt target genes such as cyclin D1, c-Myc, and MMP7. N-cadherin and TWIST, the key proteins in EMT, were upregulated, while E-cadherin expression was reduced. Additionally, proliferation, colony formation, and invasion turned out to be enhanced in NLK-overexpressing cells. After NLK knockdown in lung cancer cells, we obtained the opposite results.

Conclusion: NLK is overexpressed in lung cancers and indicates poor prognosis. Overexpression of NLK activates the Wnt signaling pathway and EMT and promotes the proliferation and invasiveness of lung cancer cells.

Keywords: Nemo-like kinase, lung cancer, wnt signaling pathway, epithelial-mesenchymal transition, proliferation, invasion.

[1]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer Statistics. CA Cancer J. Clin., 2017, 67(1), 7-30.
[2]
Chen, W.; Zheng, R.; Zeng, H.; Zhang, S.; He, J. Annual report on status of cancer in China, 2011. Chin. J. Cancer Res., 2015, 27(1), 2-12.
[3]
Larsen, J.E.; Minna, J.D. Molecular biology of lung cancer: Clinical implications. Clin. Chest Med., 2011, 32(4), 703-740.
[4]
Jones, C.M.; Brunelli, A.; Callister, M.E.; Franks, K.N. Multimodality treatment of advanced non-small cell lung cancer: Where are we with the Evidence? Curr. Surg. Rep., 2018, 6(2), 5.
[5]
Wang, L.Y.; Cui, J.J.; Guo, A.X.; Yin, J.Y. Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients. OncoTargets Ther., 2018, 11, 529-538.
[6]
Brott, B.K.; Pinsky, B.A.; Erikson, R.L. Nlk is a murine protein kinase related to Erk/MAP kinases and localized in the nucleus. Proc. Natl. Acad. Sci. USA, 1998, 95(3), 963-968.
[7]
Ishitani, T.; Ishitani, S. Nemo-like kinase, a multifaceted cell signaling regulator. Cell. Signal., 2013, 25(1), 190-197.
[8]
Huang, Y.; Yang, Y.; He, Y.; Li, J. The emerging role of Nemo-like kinase (NLK) in the regulation of cancers. Tumour Biol., 2015, 36(12), 9147-9152.
[9]
Emami, K.H.; Brown, L.G.; Pitts, T.E.; Sun, X.; Vessella, R.L.; Corey, E. Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells. The Prostate, 2009, 69(14), 1481-1492.
[10]
Cui, G.; Li, Z.; Shao, B.; Zhao, L.; Zhou, Y.; Lu, T.; Wang, J.; Shi, X.; Wang, J.; Zuo, G.; Zhu, W.; Shen, A. Clinical and biological significance of nemo-like kinase expression in glioma. J. Clin. Neurosci., 2011, 18(2), 271-275.
[11]
Huang, Y.; Jiang, Y.; Lu, W.; Zhang, Y. Nemo-like kinase associated with proliferation and apoptosis by c-Myb degradation in breast cancer. PLoS One, 2013, 8(7), e69148.
[12]
Chen, S.; Ma, Z.; Chen, X.; Zhang, J. Prognostic significance of nemo-like kinase in nasopharyngeal carcinoma. Mol. Med. Rep., 2014, 10(1), 131-136.
[13]
Yang, W.; Gu, L.; Yang, C.; Liu, T. Expression of Nemo-like kinase in cervical squamous cell carcinoma: a clinicopathological study. OncoTargets Ther., 2018, 11, 743-749.
[14]
Zhang, W.; He, J.; Du, Y.; Gao, X.H.; Liu, Y.; Liu, Q.Z.; Chang, W.J.; Cao, G.W.; Fu, C.G. Upregulation of nemo-like kinase is an independent prognostic factor in colorectal cancer. World J. Gastroenterol., 2015, 21(29), 8836-8847.
[15]
Tan, Z.; Li, M.; Wu, W.; Zhang, L.; Ding, Q.; Wu, X.; Mu, J.; Liu, Y. NLK is a key regulator of proliferation and migration in gallbladder carcinoma cells. Mol. Cell. Biochem., 2012, 369(1-2), 27-33.
[16]
Lv, M.; Li, Y.; Tian, X.; Dai, S.; Sun, J.; Jin, G.; Jiang, S. Lentivirus-mediated knockdown of NLK inhibits small-cell lung cancer growth and metastasis. Drug Des. Devel. Ther., 2016, 10, 3737-3746.
[17]
Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 1976, 72, 248-254.
[18]
Wang, Y.; Lei, L.; Zheng, Y.W.; Zhang, L.; Li, Z.H.; Shen, H.Y.; Jiang, G.Y.; Zhang, X.P.; Wang, E.H.; Xu, H.T. Odd-skipped related 1 inhibits lung cancer proliferation and invasion by reducing Wnt signaling through the suppression of SOX9 and beta-catenin. Cancer Sci., 2018, 109(6), 1799-1810.
[19]
Han, Q.; Kremerskothen, J.; Lin, X.; Zhang, X.; Rong, X.; Zhang, D.; Wang, E. WWC3 inhibits epithelial-mesenchymal transition of lung cancer by activating Hippo-YAP signaling. OncoTargets Ther., 2018, 11, 2581-2591.
[20]
Lanczky, A.; Nagy, A.; Bottai, G.; Munkacsy, G.; Szabo, A.; Santarpia, L.; Gyorffy, B. miRpower: A web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res. Treat., 2016, 160(3), 439-446.
[21]
Suwei, D.; Liang, Z.; Zhimin, L.; Ruilei, L.; Yingying, Z.; Zhen, L.; Chunlei, G.; Zhangchao, L.; Yuanbo, X.; Jinyan, Y.; Gaofeng, L.; Xin, S. NLK functions to maintain proliferation and stemness of NSCLC and is a target of metformin. J. Hematol. Oncol., 2015, 8, 120.
[22]
Lv, L.; Wan, C.; Chen, B.; Li, M.; Liu, Y.; Ni, T.; Yang, Y.; Liu, Y.; Cong, X.; Mao, G.; Xue, Q. Nemo-like kinase (NLK) inhibits the progression of NSCLC via negatively modulating WNT signaling pathway. J. Cell. Biochem., 2014, 115(1), 81-92.
[23]
Zhang, X.W.; Chen, S.Y.; Xue, D.W.; Xu, H.H.; Yang, L.H.; Xu, H.T.; Wang, E.H. Expression of Nemo-like kinase was increased and negatively correlated with the expression of TCF4 in lung cancers. Int. J. Clin. Exp. Pathol., 2015, 8(11), 15086-15092.
[24]
Zuccarini, M.; Giuliani, P.; Ziberi, S.; Carluccio, M.; Iorio, P.D.; Caciagli, F.; Ciccarelli, R. The Role of Wnt signal in glioblastoma development and progression: a possible new pharmacological target for the therapy of this tumor. Genes , 2018, 9(2)
[25]
Jamieson, C.; Sharma, M.; Henderson, B.R. Targeting the beta-catenin nuclear transport pathway in cancer. Semin. Cancer Biol., 2014, 27, 20-29.
[26]
John, R.R.; Malathi, N.; Ravindran, C.; Anandan, S. Mini review: Multifaceted role played by cyclin D1 in tumor behavior. Indian J. Dent. Res., 2017, 28(2), 187-192.
[27]
Banday, M.Z.; Sameer, A.S.; Mir, A.H.; Mokhdomi, T.A.; Chowdri, N.A.; Haq, E. Matrix metalloproteinase (MMP) -2, -7 and -9 promoter polymorphisms in colorectal cancer in ethnic Kashmiri population - A case-control study and a mini review. Gene, 2016, 589(1), 81-89.
[28]
Ishitani, T.; Ninomiya-Tsuji, J.; Matsumoto, K. Regulation of lymphoid enhancer factor 1/T-cell factor by mitogen-activated protein kinase-related Nemo-like kinase-dependent phosphorylation in Wnt/beta-catenin signaling. Mol. Cell. Biol., 2003, 23(4), 1379-1389.
[29]
Ota, S.; Ishitani, S.; Shimizu, N.; Matsumoto, K.; Itoh, M.; Ishitani, T. NLK positively regulates Wnt/beta-catenin signalling by phosphorylating LEF1 in neural progenitor cells. EMBO J., 2012, 31(8), 1904-1915.
[30]
Hotz, B.; Arndt, M.; Dullat, S.; Bhargava, S.; Buhr, H.J.; Hotz, H.G. Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. Clin. Cancer Res., 2007, 13(16), 4769-4776.
[31]
Zheng, X.; Carstens, J.L.; Kim, J.; Scheible, M.; Kaye, J.; Sugimoto, H.; Wu, C.C.; LeBleu, V.S.; Kalluri, R. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature, 2015, 527(7579), 525-530.
[32]
Wang, S.; Huang, S.; Sun, Y.L. Epithelial-mesenchymal transition in pancreatic cancer: A review. BioMed Res. Int., 2017, 2017, 2646148.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 8
Year: 2019
Page: [674 - 680]
Pages: 7
DOI: 10.2174/1568009618666181119150521
Price: $58

Article Metrics

PDF: 32
HTML: 3